We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+16.83%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$2.49B
AUM Growth
+$21.6M
Cap. Flow
+$155M
Cap. Flow %
6.21%
Top 10 Hldgs %
58.42%
Holding
119
New
16
Increased
22
Reduced
16
Closed
17

Top Buys

Rank Stock Value
1
MORF
Morphic Holding, Inc. Common Stock
MORF
+$27.6M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$23.7M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$18.2M
4
MDCO
Medicines Co
MDCO
+$16M
5
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
+$14.8M

Top Sells

Rank Stock Value
1
NVDA icon
NVIDIA
NVDA
+$37M
2
AVTR icon
Avantor
AVTR
+$16.9M
3
Z icon
Zillow
Z
+$13.9M
4
BPMC
Blueprint Medicines
BPMC
+$13M
5
HTHT icon
Huazhu Hotels Group
HTHT
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 49.17%
2 Consumer Discretionary 26.12%
3 Technology 2.9%
4 Communication Services 0.91%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLUE
51
DELISTED
bluebird bio
BLUE
$9.18M 0.37%
7,720
– –
NKTR icon
52
Nektar Therapeutics
NKTR
$2.28B
$9.11M 0.37%
33,333
-13,334
-29% -$4.89M
ALBO
53
DELISTED
Albireo Pharma Inc
ALBO
$9M 0.36%
450,200
+200
+0% +$5.18K
MRUS
54
DELISTED
Merus
MRUS
$8.91M 0.36%
500,000
+150,000
+43% +$2.46M
HOOK
55
DELISTED
HOOKIPA Pharma
HOOK
$8.51M 0.34%
113,462
– –
REPL icon
56
Replimune Group
REPL
$426M
$8.34M 0.33%
600,000
– –
MRNA icon
57
CALL
Moderna
MRNA
$21.7B
$7.96M 0.32%
500,000
– –
NERV icon
58
Minerva Neurosciences
NERV
$193M
$7.75M 0.31%
+125,000
New +$7.08M
PRQR icon
59
ProQR Therapeutics
PRQR
$241M
$7.49M 0.3%
1,300,000
– –
TBIO
60
DELISTED
Translate Bio, Inc. Common Stock
TBIO
$7.43M 0.3%
750,000
– –
TCRR
61
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$7.09M 0.28%
471,846
-18,154
-4% -$283K
KLDO
62
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$6.78M 0.27%
900,500
– –
SWTX
63
DELISTED
SpringWorks Therapeutics
SWTX
$6.69M 0.27%
+308,526
New +$7.29M
KYNB
64
Kyntra Bio
KYNB
$28.1M
$6.66M 0.27%
7,200
– –
AGEN
65
Agenus
AGEN
$277M
$6.45M 0.26%
127,375
– –
AUTL
66
Autolus Therapeutics
AUTL
$378M
$6.21M 0.25%
500,000
– –
DNLI icon
67
Denali Therapeutics
DNLI
$3.76B
$6.13M 0.25%
400,000
– –
ARQL
68
DELISTED
Arqule Inc
ARQL
$6.09M 0.24%
850,000
+150,000
+21% +$1.41M
SPRO icon
69
Spero Therapeutics
SPRO
$68.3M
$5.72M 0.23%
540,000
– –
KRYS icon
70
Krystal Biotech
KRYS
$10.6B
$5.21M 0.21%
150,000
-150,000
-50% -$6.71M
RGNX icon
71
Regenxbio
RGNX
$612M
$5.16M 0.21%
145,000
– –
TGTX icon
72
TG Therapeutics
TGTX
$8.15B
$5.05M 0.2%
900,000
– –
ACIU icon
73
AC Immune
ACIU
$230M
$4.95M 0.2%
1,000,000
– –
ADPT icon
74
Adaptive Biotechnologies
ADPT
$3.5B
$4.63M 0.19%
150,000
-50,000
-25% -$2.04M
LGF.A
75
CALL
DELISTED
Lions Gate Entertainment Corp. Class A Voting Shares
LGF.A
$4.63M 0.19%
+500,000
New +$5.69M
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2019 Portfolio in Review

As of Q3 2019, Artal Group held 119 positions worth $2.49B, up 0.87% from $2.47B the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Artal Group deployed $155M of net new capital in Q3 2019, opening 16 new positions and adding to 22 existing holdings. Its largest new stake was Global Blood Therapeutics, Inc.: 350,000 shares worth $17M.

By sector, the portfolio is most concentrated in Healthcare at 49% of assets, down from 63% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was NVIDIA, an estimated $37M trimmed.

  • Artal Group's largest Q3 2019 buy was Global Blood Therapeutics, Inc.: 350,000 shares worth $17M.
  • Artal Group added most to Morphic Holding, Inc. Common Stock in Q3 2019, an estimated $27.6M increase.
  • Artal Group's biggest Q3 2019 reduction was NVIDIA, cutting an estimated $37M.
  • Artal Group fully exited Huazhu Hotels Group in Q3 2019, selling an estimated $12.7M.
  • Artal Group's ten largest holdings make up 58% of its $2.49B portfolio in Q3 2019.
  • Artal Group opened 16 new positions and closed 17 in Q3 2019.
  • Artal Group's portfolio value rose 0.87% quarter-over-quarter to $2.49B.

Based on Artal Group's 13F filing for Q3 2019, filed 14 Nov 2019.